Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10478463rdf:typepubmed:Citationlld:pubmed
pubmed-article:10478463lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0226896lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0205531lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0000854lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C1527415lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0033262lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0007560lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:10478463lifeskim:mentionsumls-concept:C0968379lld:lifeskim
pubmed-article:10478463pubmed:issue8lld:pubmed
pubmed-article:10478463pubmed:dateCreated1999-10-22lld:pubmed
pubmed-article:10478463pubmed:abstractTextCeftizoxime (CZX), a parenteral cephalosporin, has potent and broad antibacterial activity. To improve its oral absorption, we synthesized a series of monofunctional and bifunctional prodrugs of CZX. In rabbits, urinary recovery after oral administration of CZX was improved by esterification of the carboxyl group at the C-4 position with various lipophilic moieties (monofunctional prodrugs), and was further increased by introduction of a hydrophilic L-alanine to the amino group on the thiazole ring at the C-7 position (bifunctional prodrugs). Least-squares analysis showed good parabolic correlations between log P and urinary recovery for monofunctional and bifunctional prodrugs, respectively. AS-924, a bifunctional prodrug with a pivaloyloxymethyl and L-alanyl moiety had the best balance of lipophilicity and water-solubility for oral absorption among the prodrugs synthesized.lld:pubmed
pubmed-article:10478463pubmed:languageenglld:pubmed
pubmed-article:10478463pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10478463pubmed:citationSubsetIMlld:pubmed
pubmed-article:10478463pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10478463pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10478463pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10478463pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10478463pubmed:statusMEDLINElld:pubmed
pubmed-article:10478463pubmed:monthAuglld:pubmed
pubmed-article:10478463pubmed:issn0009-2363lld:pubmed
pubmed-article:10478463pubmed:authorpubmed-author:KitagawaMMlld:pubmed
pubmed-article:10478463pubmed:authorpubmed-author:KasaiMMlld:pubmed
pubmed-article:10478463pubmed:authorpubmed-author:NishimuraKKlld:pubmed
pubmed-article:10478463pubmed:authorpubmed-author:MoriNNlld:pubmed
pubmed-article:10478463pubmed:authorpubmed-author:SakaiAAlld:pubmed
pubmed-article:10478463pubmed:authorpubmed-author:HatanoSSlld:pubmed
pubmed-article:10478463pubmed:authorpubmed-author:SugiharaTTlld:pubmed
pubmed-article:10478463pubmed:authorpubmed-author:YoshimiAAlld:pubmed
pubmed-article:10478463pubmed:issnTypePrintlld:pubmed
pubmed-article:10478463pubmed:volume47lld:pubmed
pubmed-article:10478463pubmed:ownerNLMlld:pubmed
pubmed-article:10478463pubmed:authorsCompleteYlld:pubmed
pubmed-article:10478463pubmed:pagination1081-8lld:pubmed
pubmed-article:10478463pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:meshHeadingpubmed-meshheading:10478463...lld:pubmed
pubmed-article:10478463pubmed:year1999lld:pubmed
pubmed-article:10478463pubmed:articleTitleAS-924, a novel orally active bifunctional prodrug of ceftizoxime. Synthesis and relationship between physicochemical properties and oral absorption.lld:pubmed
pubmed-article:10478463pubmed:affiliationResearch Laboratories, Kyoto Pharmaceutical Industries, Ltd., Japan.lld:pubmed
pubmed-article:10478463pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10478463pubmed:publicationTypeIn Vitrolld:pubmed